You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTramadol
Accession NumberDB00193  (APRD00028)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA narcotic analgesic proposed for moderate to severe pain. It may be habituating. [PubChem] Tramadol is also prepared as a variable release capsules, marketed under the brand name ConZip. For example, a 150 mg capsule will contain 37.5 mg of the immediate release form and 112.5 mg of the extended release form.
Structure
Thumb
Synonyms
(+)-Tramadol
(+)-trans-2-(Dimethylaminomethyl)-1-(m-methoxyphenyl)cyclohexanol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Conzipcapsule, extended release200 mg/1oralVertical Pharmaceuticals Inc.2011-08-31Not applicableUs
Conzipcapsule, extended release300 mg/1oralVertical Pharmaceuticals, LLC2011-08-31Not applicableUs
Conzipcapsule, extended release300 mg/1oralVertical Pharmaceuticals Inc.2011-08-31Not applicableUs
Conzipcapsule, extended release100 mg/1oralVertical Pharmaceuticals, LLC2011-08-31Not applicableUs
Conzipcapsule, extended release100 mg/1oralVertical Pharmaceuticals Inc.2011-08-31Not applicableUs
Conzipcapsule, extended release200 mg/1oralVertical Pharmaceuticals, LLC2011-08-31Not applicableUs
Durelacapsule (extended release)100 mgoralCipher Pharmaceuticals Inc2012-03-19Not applicableCanada
Durelacapsule (extended release)200 mgoralCipher Pharmaceuticals Inc2012-03-19Not applicableCanada
Durelacapsule (extended release)300 mgoralCipher Pharmaceuticals Inc2012-03-19Not applicableCanada
Raliviatablet (extended-release)200 mgoralValeant Canada Lp Valeant Canada S.E.C.2007-10-25Not applicableCanada
Raliviatablet (extended-release)300 mgoralValeant Canada Lp Valeant Canada S.E.C.2007-10-25Not applicableCanada
Raliviatablet (extended-release)100 mgoralValeant Canada Lp Valeant Canada S.E.C.2007-10-25Not applicableCanada
Ryzolttablet, extended release100 mg/1oralStat Rx USA2008-12-30Not applicableUs
Ryzolttablet, extended release300 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-22Not applicableUs
Ryzolttablet, extended release300 mg/1oralStat Rx USA2008-12-30Not applicableUs
Ryzolttablet, extended release200 mg/1oralStat Rx USA2008-12-30Not applicableUs
Taro-tramadol ERtablet (extended-release)300 mgoralTaro Pharmaceuticals Inc2016-05-27Not applicableCanada
Taro-tramadol ERtablet (extended-release)100 mgoralTaro Pharmaceuticals Inc2016-03-07Not applicableCanada
Taro-tramadol ERtablet (extended-release)200 mgoralTaro Pharmaceuticals Inc2016-05-27Not applicableCanada
Tramadol Hydrochloridecapsule, extended release150 mg/1oralA S Medication Solutions Llc2012-03-14Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralPatriot Pharmaceuticals, LLC2006-01-16Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralA S Medication Solutions Llc2012-03-14Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralH.J. Harkins Company, Inc.2012-03-14Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralProficient Rx LP2012-03-14Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralUnit Dose Services2015-07-01Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralUnit Dose Services2012-03-14Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralKLE 2, Inc.2012-03-142015-12-29Us
Tramadol Hydrochloridetablet, extended release200 mg/1oralPatriot Pharmaceuticals, LLC2006-01-16Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-03-14Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralAidarex Pharmaceuticals LLC2012-03-14Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralPreferred Pharmaceuticals Inc.2015-09-18Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralbryant ranch prepack2012-03-14Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralPatriot Pharmaceuticals, LLC2006-01-16Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralMedsource Pharmaceuticals2012-03-14Not applicableUs
Tramadol Hydrochloridecapsule, coated, extended release150 mg/1oralDIRECT RX2014-01-01Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralProficient Rx LP2015-07-01Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralPreferred Pharmaceuticals, Inc.2012-07-17Not applicableUs
Tramadol Hydrochloridecapsule150 mg/1oralDIRECT RX2015-01-01Not applicableUs
Tramadol Hydrochloridecapsule, extended release150 mg/1oralSta3, Llc2015-07-01Not applicableUs
Tramadol Hydrochloride Extended-releasecapsule200 mg/1oralTrigen Laboratories, LLC2015-06-22Not applicableUs
Tramadol Hydrochloride Extended-releasecapsule300 mg/1oralTrigen Laboratories, LLC2015-06-22Not applicableUs
Tramadol Hydrochloride Extended-releasecapsule100 mg/1oralTrigen Laboratories, LLC2015-06-22Not applicableUs
Triduraltablet (extended-release)100 mgoralPaladin Labs Inc2007-08-14Not applicableCanada
Triduraltablet (extended-release)200 mgoralPaladin Labs Inc2007-08-14Not applicableCanada
Triduraltablet (extended-release)300 mgoralPaladin Labs Inc2007-08-14Not applicableCanada
Ultramtablet, coated50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-03-20Not applicableUs
Ultramtablet, coated50 mg/1oralPd Rx Pharmaceuticals, Inc.1995-03-03Not applicableUs
Ultramtablet, coated50 mg/1oralJanssen Pharmaceuticals, Inc.1995-03-03Not applicableUs
Ultramtablet50 mgoralJanssen Inc2010-06-28Not applicableCanada
Ultramtablet, coated50 mg/1oralA S Medication Solutions Llc1995-03-03Not applicableUs
Ultramtablet, coated50 mg/1oralA S Medication Solutions Llc1995-03-03Not applicableUs
Ultram ERtablet, extended release300 mg/1oralRebel Distributors Corp2005-09-08Not applicableUs
Ultram ERtablet, extended release300 mg/1oralJanssen Pharmaceuticals, Inc.2005-10-01Not applicableUs
Ultram ERtablet, extended release200 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-20Not applicableUs
Ultram ERtablet, extended release100 mg/1oralJanssen Pharmaceuticals, Inc.2005-10-01Not applicableUs
Ultram ERtablet, extended release100 mg/1oralRebel Distributors Corp2005-09-08Not applicableUs
Ultram ERtablet, extended release100 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-27Not applicableUs
Ultram ERtablet, extended release200 mg/1oralRebel Distributors Corp2005-09-08Not applicableUs
Ultram ERtablet, extended release200 mg/1oralJanssen Pharmaceuticals, Inc.2005-10-01Not applicableUs
Ultram ERtablet100 mg/1oralREMEDYREPACK INC.2012-03-01Not applicableUs
Ultram ERtablet, extended release300 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-27Not applicableUs
Zytram XLtablet (extended-release)100 mgoralPurdue Pharma2011-03-02Not applicableCanada
Zytram XLtablet (extended-release)200 mgoralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLtablet (extended-release)300 mgoralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLtablet (extended-release)400 mgoralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLtablet (extended-release)150 mgoralPurdue Pharma2006-12-07Not applicableCanada
Zytram XLtablet (extended-release)75 mgoralPurdue Pharma2011-03-02Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tramadoltablet50 mgoralApotex Inc2014-06-23Not applicableCanada
Tramadoltablet50 mg/1oralAccord Healthcare, Inc.2013-10-01Not applicableUs
Tramadol ERtablet, extended release200 mg/1oralStat Rx USA2009-10-27Not applicableUs
Tramadol Hydrchloridetablet50 mg/1oralREMEDYREPACK INC.2011-09-28Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralProficient Rx LP2011-12-12Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralLife Line Home Care Services, Inc.2011-01-01Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-06-01Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2013-06-04Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralCardinal Health2011-02-04Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralSun Pharma Global FZE2011-12-30Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralREMEDYREPACK INC.2015-04-02Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralAurobindo Pharma Limited2014-03-31Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralBiomes Pharmaceuticals LLC2016-02-25Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralPreferred Pharmaceuticals Inc.2015-09-22Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralTeva Pharmaceuticals USA Inc2002-06-20Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralRebel Distributors Corp.2009-11-13Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralUnit Dose Services2011-09-21Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralPhysicians Total Care, Inc.2002-06-21Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralSTAT Rx USA LLC2009-11-23Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralA S Medication Solutions Llc2002-06-22Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralSun Pharmaceutical Industries, Inc.2002-06-22Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-02-07Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralLupin Pharmaceuticals, Inc.2014-08-18Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralLupin Pharmaceuticals, Inc.2011-09-262015-12-31Us
Tramadol Hydrochloridetablet, film coated50 mg/1oralMajor Pharmaceuticals2014-02-26Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralAidarex Pharmaceuticals LLC2002-06-22Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralMylan Institutional Inc.2002-08-01Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralCardinal Health2010-03-01Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralSun Pharma Global FZE2011-12-12Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralDispensing Solutions, Inc.2002-06-22Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralNorthstar Rx LLC2016-04-06Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-15Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralCardinal Health2002-06-21Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralPar Pharmaceutical Inc.2009-11-13Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralbryant ranch prepack2002-06-22Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralLupin Pharmaceuticals, Inc.2011-09-26Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralMc Kesson Contract Packaging2011-10-19Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralBlenheim Pharmacal, Inc.2010-08-13Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-06-01Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2013-05-07Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralUnit Dose Services2011-12-30Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralPhysicians Total Care, Inc.2010-11-17Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralSun Pharma Global FZE2011-12-30Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2015-12-10Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralAurobindo Pharma Limited2015-10-20Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralMylan Pharmaceuticals Inc.2016-03-16Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralPreferred Pharmaceuticals, Inc.2009-11-23Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.2002-06-21Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralRebel Distributors Corp.2009-11-13Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralNorthstar Rx LLC2011-02-16Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralPd Rx Pharmaceuticals, Inc.2010-11-15Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralA S Medication Solutions Llc2002-06-22Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralApotex Corp.2002-07-10Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralA S Medication Solutions Llc2002-06-22Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralReady Meds2010-11-15Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralDispensing Solutions, Inc.2009-11-13Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralMacleods Pharmaceuticals Limited2015-10-07Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralMed Health Pharma, LLC2011-01-01Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralCardinal Health2002-06-22Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralSun Pharma Global FZE2011-12-12Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralContract Pharmacy Services Pa2010-02-26Not applicableUs
Tramadol Hydrochloridetablet50 mg/50mgoralAlivio Medical Products, Llc2015-10-01Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-11-23Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralPd Rx Pharmaceuticals, Inc.2010-11-15Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralPar Pharmaceutical Inc.2009-11-13Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralbryant ranch prepack2010-11-15Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralLupin Pharmaceuticals, Inc.2014-08-18Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralVirtus Pharmaceuticals LLC2014-02-20Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralBlenheim Pharmacal, Inc.2010-04-07Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-06-21Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2011-12-05Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralUnit Dose Services2010-11-15Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralCardinal Health2010-11-15Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralSun Pharma Global FZE2011-12-30Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralAurobindo Pharma Limited2015-10-20Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralMylan Pharmaceuticals Inc.2016-03-16Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralPreferred Pharmaceuticals, Inc.2014-10-06Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralAphena Pharma Solutions Tennessee, Llc2010-11-15Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralA S Medication Solutions Llc2009-11-13Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralSt. Mary's Medical Park Pharmacy2014-10-06Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralA S Medication Solutions Llc2002-06-22Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralAmneal Pharmaceuticals of New York, LLC2010-11-15Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralZydus Pharmaceuticals (USA) Inc.2011-01-31Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralApotheca, Inc2005-04-26Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralRx Change Co.2014-11-14Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralCardinal Health2010-03-23Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2010-11-17Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralProficient Rx LP2010-11-15Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralAmerican Health Packaging2014-08-21Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralVirtus Pharmaceuticals2015-05-22Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralSTAT Rx USA LLC2002-06-22Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-12-12Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralREMEDYREPACK INC.2014-01-09Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-12-12Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralPar Pharmaceutical Inc.2011-09-21Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2013-12-02Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralLupin Pharmaceuticals, Inc.2014-08-18Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralLupin Pharmaceuticals, Inc.2011-09-262015-11-30Us
Tramadol Hydrochloridetablet50 mg/1oralMajor Pharmaceuticals2010-03-01Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralAidarex Pharmaceuticals LLC2010-11-15Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralUnit Dose Services2011-12-30Not applicableUs
Tramadol Hydrochloridetablet, coated50 mg/1oralCardinal Health2010-11-15Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralSun Pharma Global FZE2011-12-12Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralAurobindo Pharma Limited2015-10-20Not applicableUs
Tramadol Hydrochloridetablet, extended release300 mg/1oralMylan Pharmaceuticals Inc.2016-03-16Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralPreferred Pharmaceuticals, Inc.2014-10-06Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralCitron Pharma LLC2014-03-31Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralRebel Distributors Corp.2009-11-23Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralMedsource Pharmaceuticals2014-02-14Not applicableUs
Tramadol Hydrochloridetablet, extended release200 mg/1oralPhysicians Total Care, Inc.2010-03-08Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2015-02-26Not applicableUs
Tramadol Hydrochloridetablet, extended release100 mg/1oralA S Medication Solutions Llc2009-11-13Not applicableUs
Tramadol Hydrochloridetablet, film coated50 mg/1oralCadila Healthcare Limited2011-01-31Not applicableUs
Tramadol Hydrochloridetablet50 mg/1oralKeltman Pharmaceuticals Inc.2009-06-30Not applicableUs
Tramadol Hydrochloride ERtablet, extended release100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Tramadol Hydrochloride Extended-releasetablet, film coated, extended release300 mg/1oralPar Pharmaceutical, Inc.2012-06-27Not applicableUs
Tramadol Hydrochloride Extended-releasetablet, film coated, extended release100 mg/1oralPar Pharmaceutical, Inc.2012-06-27Not applicableUs
Tramadol Hydrochloride Extended-releasetablet, film coated, extended release200 mg/1oralPar Pharmaceutical, Inc.2012-06-27Not applicableUs
Ultramtablet, coated50 mg/201oralNorthwind Pharmaceuticals2014-02-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SynaprynkitoralFusion Pharmaceuticals LLC2009-09-14Not applicableUs
International Brands
NameCompany
RybixNot Available
TramalGrünenthal GmbH
Brand mixtures
NameLabellerIngredients
Act Tramadol/acetActavis Pharma Company
Apo-tramadol/acetApotex Inc
Auro-tramadol/acetaminophenAuro Pharma Inc
Direct RxDIRECT RX
Ipg-tramadol/acetMarcan Pharmaceuticals Inc
Jamp-acet-tramadolJamp Pharma Corporation
Lupin-tramadol/acetLupin Pharma Canada Limited
Mar-tramadol/acetMarcan Pharmaceuticals Inc
Mint-tramadol/acetMint Pharmaceuticals Inc
Mylan-tramadol/acetMylan Pharmaceuticals Ulc
Pat-tramadol/acetPatriot A Division Of Janssen Inc
PMS-tramadol-acetPharmascience Inc
Priva-tramadol/acetPharmapar Inc
Ran-tramadol/acetRanbaxy Pharmaceuticals Canada Inc.
Riva-tramadol/acetLaboratoire Riva Inc
Teva-tramadol/acetaminophenTeva Canada Limited
Theratramadol-90Physician Therapeutics Llc
TramacetJanssen Inc
Tramadal Hydrochloride and AcetaminophenREMEDYREPACK INC.
Tramadol / AcetaminophenSivem Pharmaceuticals Ulc
Tramadol Hydrochloride and AcetaminophenMylan Pharmaceuticals Inc.
Tramadol-acetPro Doc Limitee
Tramadol/acetSanis Health Inc
TramapapLiving Well Pharmacy, Inc.
Tramaphen-odanOdan Laboratories Ltd
UltracetRebel Distributors Corp
Salts
Name/CASStructureProperties
Tramadol Hydrochloride
Thumb
  • InChI Key: PPKXEPBICJTCRU-XMZRARIVSA-N
  • Monoisotopic Mass: 299.165206788
  • Average Mass: 299.836
DBSALT000181
Categories
UNII39J1LGJ30J
CAS number27203-92-5
WeightAverage: 263.3752
Monoisotopic: 263.188529049
Chemical FormulaC16H25NO2
InChI KeyInChIKey=TVYLLZQTGLZFBW-ZBFHGGJFSA-N
InChI
InChI=1S/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1
IUPAC Name
(1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol
SMILES
COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentAnisoles
Alternative Parents
Substituents
  • Methoxybenzene
  • Anisole
  • Aralkylamine
  • Cyclohexanol
  • Alkyl aryl ether
  • Tertiary alcohol
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
  • 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol (CHEBI:75725 )
Pharmacology
IndicationIndicated in the treatment of moderate to severe pain. Consider for those prone to constipation or respiratory depression. Tramadol is used to treat postoperative, dental, cancer, and acute musculosketetal pain and as an adjuvant to NSAID therapy in patients with osteoarthritis.
PharmacodynamicsTramadol, a centrally-acting analgesic, exists as a racemic mixture of the trans isomer, with important differences in binding, activity, and metabolism associated with the two enantiomers. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to μ-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin. Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to μ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in μ-opioid binding. Opiate antagonist naloxone only partially antagonized tramadol-induced analgesia.
Mechanism of actionTramadol and its O-desmethyl metabolite (M1) are selective, weak OP3-receptor agonists. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. The analgesic properties of Tramadol can be attributed to norepinephrine and serotonin reuptake blockade in the CNS, which inhibits pain transmission in the spinal cord. The (+) enantiomer has higher affinity for the OP3 receptor and preferentially inhibits serotonin uptake and enhances serotonin release. The (-) enantiomer preferentially inhibits norepinephrine reuptake by stimulating alpha(2)-adrenergic receptors.
Related Articles
AbsorptionRacemic tramadol is rapidly and almost completely absorbed after oral administration. The mean absolute bioavailability of a 100 mg oral dose is approximately 75%. The mean peak plasma concentration of racemic tramadol and M1 occurs at two and three hours, respectively, after administration in healthy adults.
Volume of distribution
  • 2.6 L/kg [male, 100 mg intravenous dose]
  • 2.9 L/kg [female, 100 mg intravenous dose]
Protein binding20% bound to plasma proteins.
Metabolism

Hepatic. The major metabolic pathways appear to be N- and O- demethylation and glucuronidation or sulfation in the liver. One metabolite (O-desmethyltramadol, denoted M1) is pharmacologically active in animal models. CYP3A4 and CYP2B6 facilitates the biotransformation of tramadol to N-desmethyl-tramadol. CYP2D6 facilitates the biotransformation of tramadol to O-desmethyl-tramadol.

SubstrateEnzymesProduct
Tramadol
O-DesmethyltramadolDetails
Tramadol
N-DesmethyltramadolDetails
O-Desmethyltramadol
O-Desmethyl-tramado glucuronideDetails
O-Desmethyltramadol
N,O-didesmethyltramadolDetails
N-Desmethyltramadol
N,O-didesmethyltramadolDetails
N-Desmethyltramadol
N,N-didesmethyltramadolDetails
N,O-didesmethyltramadol
Not Available
N,N,O-tridesmethyl-tramadolDetails
N,N-didesmethyltramadol
Not Available
N,N,O-tridesmethyl-tramadolDetails
Route of eliminationTramadol is eliminated primarily through metabolism by the liver and the metabolites are excreted primarily by the kidneys. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites.
Half lifeTramadol and its metabolites are excreted primarily in the urine with observed plasma half-lives of 6.3 and 7.4 hours for tramadol and M1, respectively.
Clearance
  • 5.9 mL/min/Kg [Healthy Adults, 100 mg qid, MD p.o]
  • 8.5 mL/min/Kg [Healthy Adults, 100 mg SD p.o]
  • 6.89 mL/min/Kg [Geriatric, (<75 yr), 50 mg SD p.o.]
  • 4.23 mL/min/Kg [Hepatic Impaired, 50 mg SD p.o.]
  • 4.23 mL/min/Kg [Renal Impaired, Clcr10-3mL/min, 100 mg SD i.v.]
  • 3.73 mL/min/Kg [Renal Impaired, CLcr<5 mL/min, 100 mg SD i.v.]
  • 6.4 mL/min/Kg [Male following a 100 mg IV dose]
  • 5.7 mL/min/Kg [Female following a 100 mg IV dose]
ToxicityLD50=350mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Tramadol Metabolism PathwayDrug metabolismSMP00637
Tramadol Action Action PathwayDrug actionSMP00671
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9924
Blood Brain Barrier+0.9382
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.6283
P-glycoprotein inhibitor IInhibitor0.7807
P-glycoprotein inhibitor IIInhibitor0.9589
Renal organic cation transporterNon-inhibitor0.6398
CYP450 2C9 substrateNon-substrate0.7678
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7726
CYP450 1A2 substrateNon-inhibitor0.7136
CYP450 2C9 inhibitorNon-inhibitor0.704
CYP450 2D6 inhibitorInhibitor0.6566
CYP450 2C19 inhibitorNon-inhibitor0.6841
CYP450 3A4 inhibitorNon-inhibitor0.6256
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7832
Ames testNon AMES toxic0.7899
CarcinogenicityNon-carcinogens0.6663
BiodegradationNot ready biodegradable0.9975
Rat acute toxicity3.0316 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6136
hERG inhibition (predictor II)Inhibitor0.7098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Cipher pharmaceuticals inc
  • Purdue pharma products lp
  • Par pharmaceutical
  • Biovail laboratories international srl
  • Victory pharma inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Amneal pharmaceuticals llc
  • Apotex inc
  • Asta medica inc
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mallinckrodt inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Northstar healthcare holdings ltd
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories
  • Ortho mcneil janssen pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral200 mg/1
Capsule, extended releaseoral300 mg/1
Capsule (extended release)oral100 mg
Capsule (extended release)oral200 mg
Capsule (extended release)oral300 mg
Kitoral
Capsuleoral150 mg/1
Capsule, coated, extended releaseoral150 mg/1
Capsule, extended releaseoral150 mg/1
Tabletoral50 mg/50mg
Tabletoral50 mg/1
Tablet, coatedoral50 mg/1
Tablet, extended releaseoral100 mg/1
Tablet, extended releaseoral200 mg/1
Tablet, extended releaseoral300 mg/1
Tablet, film coatedoral50 mg/1
Tablet, coatedoral
Tablet, film coatedoral
Capsuleoral100 mg/1
Capsuleoral200 mg/1
Capsuleoral300 mg/1
Tablet, film coated, extended releaseoral100 mg/1
Tablet, film coated, extended releaseoral200 mg/1
Tablet, film coated, extended releaseoral300 mg/1
Kit
Tablet (extended-release)oral100 mg
Tabletoral
Tabletoral50 mg
Tablet, coatedoral50 mg/201
Tabletoral100 mg/1
Tablet (extended-release)oral150 mg
Tablet (extended-release)oral200 mg
Tablet (extended-release)oral300 mg
Tablet (extended-release)oral400 mg
Tablet (extended-release)oral75 mg
Prices
Unit descriptionCostUnit
Tramadol hcl powder29.08USD g
Ultram ER 300 mg 24 Hour tablet10.66USD tablet
Ultram er 300 mg tablet10.25USD tablet
Ultram ER 200 mg 24 Hour tablet7.64USD tablet
Ultram er 200 mg tablet7.35USD tablet
TraMADol HCl 200 mg 24 Hour tablet6.25USD tablet
Ultram ER 100 mg 24 Hour tablet4.62USD tablet
Ultram er 100 mg tablet4.44USD tablet
TraMADol HCl 100 mg 24 Hour tablet3.78USD tablet
Ultram 50 mg tablet1.99USD tablet
Tramadol-Acetaminophen 37.5-325 mg tablet1.07USD tablet
Tramadol hcl 50 mg tablet0.7USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2123160 No2003-04-292014-05-09Canada
CA2476201 No2009-09-012023-02-21Canada
US5464632 No1993-03-222013-03-22Us
US6106861 No1997-12-052017-12-05Us
US6339105 Yes2000-04-122020-04-12Us
US6607748 No2000-06-292020-06-29Us
US7858118 No2002-04-112022-04-11Us
US7988998 No2003-10-272023-10-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point180-181 °CNot Available
water solubilitySoluble Not Available
logP2.4FDA label
pKa9.41FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.75 mg/mLALOGPS
logP2.71ALOGPS
logP2.45ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)13.8ChemAxon
pKa (Strongest Basic)9.23ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.7 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.27 m3·mol-1ChemAxon
Polarizability30.45 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9010000000-ffea37e400f0860f2e7fView in MoNA
References
Synthesis Reference

Wolfgang Reimann, “Combination preparation containing tramadol and a calcium channel antagonist.” U.S. Patent US5929122, issued March, 1993.

US5929122
General References
  1. Dayer P, Desmeules J, Collart L: [Pharmacology of tramadol]. Drugs. 1997;53 Suppl 2:18-24. [PubMed:9190321 ]
  2. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998 Jun;50(6):1842-6. [PubMed:9633738 ]
  3. Harati Y, Gooch C, Swenson M, Edelman SV, Greene D, Raskin P, Donofrio P, Cornblath D, Olson WH, Kamin M: Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications. 2000 Mar-Apr;14(2):65-70. [PubMed:10959067 ]
  4. Gobel H, Stadler T: [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine]. Drugs. 1997;53 Suppl 2:34-9. [PubMed:9190323 ]
  5. Boureau F, Legallicier P, Kabir-Ahmadi M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain. 2003 Jul;104(1-2):323-31. [PubMed:12855342 ]
External Links
ATC CodesN02AX52N02AX02
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (408 KB)
MSDSDownload (74.7 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Tramadol.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Tramadol.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINETramadol may increase the neuroexcitatory activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Abiraterone.
AcenocoumarolTramadol may increase the anticoagulant activities of Acenocoumarol.
AcepromazineAcepromazine may increase the hypotensive activities of Tramadol.
AcepromazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Acetophenazine.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tramadol.
adipiplonThe risk or severity of adverse effects can be increased when Tramadol is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Tramadol is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Alfentanil.
AlimemazineAlimemazine may increase the hypotensive activities of Tramadol.
AlmotriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Almotriptan.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Alprazolam.
AlvimopanThe risk or severity of adverse effects can be increased when Tramadol is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Tramadol is combined with Amiloride.
AmineptineAmineptine may increase the neuroexcitatory activities of Tramadol.
AmiodaroneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Tramadol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Tramadol is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Tramadol which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Amobarbital.
AmoxapineTramadol may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tramadol.
AmperozideThe risk or severity of adverse effects can be increased when Tramadol is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Tramadol.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Tramadol.
AprepitantThe serum concentration of Tramadol can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Aripiprazole.
ArtemetherThe therapeutic efficacy of Tramadol can be decreased when used in combination with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Asenapine.
AtazanavirThe serum concentration of Tramadol can be increased when it is combined with Atazanavir.
AtomoxetineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tramadol.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Tramadol.
AzaperoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Azaperone.
AzelastineTramadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tramadol.
AzosemideThe risk or severity of adverse effects can be increased when Tramadol is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Tramadol is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Tramadol.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Bendroflumethiazide.
BenmoxinTramadol may increase the neuroexcitatory activities of Benmoxin.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tramadol.
BenzocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Tramadol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Tramadol is combined with Benzyl alcohol.
BetaxololThe therapeutic efficacy of Tramadol can be decreased when used in combination with Betaxolol.
BexaroteneThe serum concentration of Tramadol can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Tramadol is combined with Bifeprunox.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Tramadol.
BoceprevirThe serum concentration of Tramadol can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Tramadol can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Tramadol can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
BrimonidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Tramadol is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Tramadol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Bupivacaine.
BuprenorphineBuprenorphine may decrease the analgesic activities of Tramadol.
BuprenorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Buprenorphine.
BupropionThe therapeutic efficacy of Tramadol can be decreased when used in combination with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Tramadol is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Butabarbital.
ButacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Tramadol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Tramadol is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Tramadol.
ButorphanolThe risk or severity of adverse effects can be increased when Tramadol is combined with Butorphanol.
CabergolineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cabergoline.
Canrenoic acidThe risk or severity of adverse effects can be increased when Tramadol is combined with Canrenoic acid.
CarbamazepineTramadol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tramadol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Carfentanil.
CariprazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Tramadol is combined with Carisoprodol.
CaroxazoneTramadol may increase the neuroexcitatory activities of Caroxazone.
CelecoxibThe therapeutic efficacy of Tramadol can be decreased when used in combination with Celecoxib.
CeritinibThe serum concentration of Tramadol can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Tramadol is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Chloroprocaine.
ChloroquineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tramadol.
ChlorphentermineChlorphentermine may increase the analgesic activities of Tramadol.
ChlorpromazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorzoxazone.
CholecalciferolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cholecalciferol.
CimetidineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cimetidine.
CinacalcetThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cinchocaine.
CitalopramThe therapeutic efficacy of Tramadol can be decreased when used in combination with Citalopram.
CitalopramTramadol may increase the serotonergic activities of Citalopram.
ClarithromycinThe serum concentration of Tramadol can be increased when it is combined with Clarithromycin.
ClemastineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Tramadol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Tramadol is combined with Clidinium.
ClobazamThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Tramadol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with clomethiazole.
ClomipramineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clomipramine.
ClomipramineTramadol may increase the serotonergic activities of Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Clonidine.
ClopidogrelThe metabolism of Tramadol can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Tramadol is combined with Clorazepate.
ClotrimazoleThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clotrimazole.
ClozapineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Clozapine.
CobicistatThe serum concentration of Tramadol can be increased when it is combined with Cobicistat.
CocaineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cocaine.
CocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Tramadol is combined with Codeine.
ConivaptanThe serum concentration of Tramadol can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Conivaptan.
CrizotinibThe metabolism of Tramadol can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tramadol.
CyclosporineThe metabolism of Tramadol can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyproheptadine.
DabrafenibThe serum concentration of Tramadol can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Tramadol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tramadol.
DapoxetineTramadol may increase the serotonergic activities of Dapoxetine.
DarifenacinThe therapeutic efficacy of Tramadol can be decreased when used in combination with Darifenacin.
DarunavirThe serum concentration of Tramadol can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Tramadol can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Tramadol can be decreased when it is combined with Deferasirox.
DelavirdineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Tramadol is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Desflurane.
DesipramineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Tramadol is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tramadol.
DesmopressinThe risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tramadol is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Detomidine.
DexamethasoneThe serum concentration of Tramadol can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tramadol.
DexmedetomidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dexmedetomidine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Tramadol.
DextromethorphanThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Tramadol is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Diazepam.
DicoumarolTramadol may increase the anticoagulant activities of Dicoumarol.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tramadol.
DifenoxinThe risk or severity of adverse effects can be increased when Tramadol is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Tramadol can be decreased when combined with Dihydroergotamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dihydromorphine.
DiltiazemThe metabolism of Tramadol can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Tramadol is combined with Dimenhydrinate.
DiphenhydramineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Tramadol is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Tramadol is combined with Diphenoxylate.
DolasetronDolasetron may decrease the analgesic activities of Tramadol.
DoramectinThe risk or severity of adverse effects can be increased when Tramadol is combined with Doramectin.
DosulepinDosulepin may increase the neuroexcitatory activities of Tramadol.
DoxepinThe risk or severity of adverse effects can be increased when Tramadol is combined with Doxepin.
DoxorubicinThe metabolism of Tramadol can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Tramadol can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
DoxylamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Tramadol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
DronedaroneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Tramadol is combined with Droperidol.
DrospirenoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Tramadol is combined with Drotebanol.
DuloxetineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Tramadol is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Tramadol is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Tramadol is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Tramadol can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Tramadol is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Tramadol is combined with Efonidipine.
EletriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Eletriptan.
EliglustatThe therapeutic efficacy of Tramadol can be decreased when used in combination with Eliglustat.
EluxadolineTramadol may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Enflurane.
EntacaponeThe risk or severity of adverse effects can be increased when Tramadol is combined with Entacapone.
EnzalutamideThe serum concentration of Tramadol can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Eplerenone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergotamine.
ErythromycinThe metabolism of Tramadol can be decreased when combined with Erythromycin.
EscitalopramEscitalopram may increase the neuroexcitatory activities of Tramadol.
EscitalopramTramadol may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Tramadol can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineEsmirtazapine may increase the neuroexcitatory activities of Tramadol.
EstazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Eszopiclone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid.
EthanolTramadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Tramadol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tramadol.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Tramadol.
EthosuximideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethoxzolamide.
Ethyl biscoumacetateTramadol may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Tramadol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Tramadol is combined with Etomidate.
EtoperidoneEtoperidone may increase the neuroexcitatory activities of Tramadol.
EtoperidoneTramadol may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Etorphine.
EtravirineThe serum concentration of Tramadol can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Tramadol is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Fencamfamine.
FenfluramineFenfluramine may increase the neuroexcitatory activities of Tramadol.
FenfluramineTramadol may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Tramadol is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tramadol.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Tramadol.
FexofenadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Tramadol is combined with Flibanserin.
FluconazoleThe metabolism of Tramadol can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Flunitrazepam.
FluoxetineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Fluoxetine.
FluoxetineTramadol may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Tramadol is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Tramadol.
FluphenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluticasone Propionate.
FluvoxamineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Fluvoxamine.
FluvoxamineTramadol may increase the serotonergic activities of Fluvoxamine.
FosamprenavirThe metabolism of Tramadol can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Tramadol can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Tramadol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Frovatriptan.
FurazolidoneTramadol may increase the neuroexcitatory activities of Furazolidone.
FurosemideThe risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide.
Fusidic AcidThe serum concentration of Tramadol can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Tramadol is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tramadol is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Tramadol.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Tramadol is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Tramadol is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Tramadol.
GranisetronGranisetron may decrease the analgesic activities of Tramadol.
GuanfacineThe risk or severity of adverse effects can be increased when Tramadol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Halazepam.
HaloperidolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Tramadol is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Tramadol is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Tramadol is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Tramadol.
HexobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Tramadol.
HydracarbazineTramadol may increase the neuroexcitatory activities of Hydracarbazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydrocodone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Tramadol.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
HydroxyzineThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tramadol.
IdelalisibThe serum concentration of Tramadol can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Iloperidone.
ImatinibThe metabolism of Tramadol can be decreased when combined with Imatinib.
ImipramineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Tramadol is combined with Imipramine.
IndalpineIndalpine may increase the neuroexcitatory activities of Tramadol.
IndalpineTramadol may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Indapamide.
IndinavirThe therapeutic efficacy of Tramadol can be decreased when used in combination with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tramadol.
IproclozideTramadol may increase the neuroexcitatory activities of Iproclozide.
IproniazidTramadol may increase the neuroexcitatory activities of Iproniazid.
IsavuconazoniumThe metabolism of Tramadol can be decreased when combined with Isavuconazonium.
IsocarboxazidTramadol may increase the neuroexcitatory activities of Isocarboxazid.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Tramadol.
IsofluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Isoflurane.
IsoniazidThe therapeutic efficacy of Tramadol can be decreased when used in combination with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Tramadol is combined with Isosorbide.
IsradipineThe metabolism of Tramadol can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Tramadol can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Tramadol can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketobemidone.
KetoconazoleThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Tramadol is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Tramadol is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Tramadol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Tramadol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Tramadol is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Tramadol is combined with Levomethadyl Acetate.
LevomilnacipranLevomilnacipran may increase the neuroexcitatory activities of Tramadol.
LevomilnacipranTramadol may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Tramadol is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Lidocaine.
LinezolidThe risk or severity of adverse effects can be increased when Tramadol is combined with Linezolid.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Tramadol.
LithiumThe risk or severity of adverse effects can be increased when Tramadol is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Lofentanil.
LopinavirThe serum concentration of Tramadol can be increased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tramadol.
LorcaserinThe therapeutic efficacy of Tramadol can be decreased when used in combination with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Tramadol is combined with Lorcaserin.
LovastatinThe metabolism of Tramadol can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Loxapine.
Lu AA21004Tramadol may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Tramadol.
LuliconazoleThe serum concentration of Tramadol can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Tramadol can be decreased when it is combined with Lumacaftor.
LumefantrineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Tramadol is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Tramadol is combined with Maprotiline.
MebanazineTramadol may increase the neuroexcitatory activities of Mebanazine.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tramadol.
MeclizineThe risk or severity of adverse effects can be increased when Tramadol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Tramadol is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Tramadol.
MepivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Tramadol is combined with Meprobamate.
MersalylThe risk or severity of adverse effects can be increased when Tramadol is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Tramadol.
MesoridazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Metaxalone.
MethadoneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Tramadol is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Tramadol.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Tramadol.
MethapyrileneThe risk or severity of adverse effects can be increased when Tramadol is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Methohexital.
MethotrimeprazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Methotrimeprazine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Tramadol is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Methyclothiazide.
Methylene blueTramadol may increase the neuroexcitatory activities of Methylene blue.
Methylene blueMethylene blue may increase the hypotensive activities of Tramadol.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Methylphenobarbital.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Tramadol.
MetoclopramideThe risk or severity of adverse effects can be increased when Tramadol is combined with Metoclopramide.
MetolazoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Tramadol.
MetoprololThe therapeutic efficacy of Tramadol can be decreased when used in combination with Metoprolol.
MetyrosineTramadol may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Midazolam.
MifepristoneThe metabolism of Tramadol can be decreased when combined with Mifepristone.
MilnacipranMilnacipran may increase the neuroexcitatory activities of Tramadol.
MilnacipranTramadol may increase the serotonergic activities of Milnacipran.
MinaprineTramadol may increase the neuroexcitatory activities of Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
MirabegronThe therapeutic efficacy of Tramadol can be decreased when used in combination with Mirabegron.
MirtazapineTramadol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tramadol.
MitotaneThe serum concentration of Tramadol can be decreased when it is combined with Mitotane.
MoclobemideTramadol may increase the neuroexcitatory activities of Moclobemide.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Tramadol.
ModafinilThe serum concentration of Tramadol can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Tramadol.
MorphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Tramadol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tramadol.
NabiloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Nabilone.
NafcillinThe serum concentration of Tramadol can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Tramadol.
NalbuphineThe risk or severity of adverse effects can be increased when Tramadol is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Naratriptan.
NefazodoneThe serum concentration of Tramadol can be increased when it is combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Nefazodone.
NelfinavirThe serum concentration of Tramadol can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Tramadol can be increased when it is combined with Netupitant.
NevirapineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nevirapine.
NialamideTramadol may increase the neuroexcitatory activities of Nialamide.
NicardipineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nicardipine.
NilotinibThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Tramadol.
NitrazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Tramadol is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Tramadol is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Tramadol.
OctamoxinTramadol may increase the neuroexcitatory activities of Octamoxin.
OlanzapineTramadol may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tramadol.
OlaparibThe metabolism of Tramadol can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Tramadol is combined with Olopatadine.
OndansetronOndansetron may decrease the analgesic activities of Tramadol.
OndansetronThe risk or severity of adverse effects can be increased when Tramadol is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Tramadol is combined with Opium.
OrphenadrineTramadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tramadol.
OsanetantThe risk or severity of adverse effects can be increased when Tramadol is combined with Osanetant.
OsimertinibThe serum concentration of Tramadol can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tramadol.
OxycodoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Tramadol.
PalbociclibThe serum concentration of Tramadol can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Paliperidone.
PalonosetronPalonosetron may decrease the analgesic activities of Tramadol.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Tramadol.
PanobinostatThe therapeutic efficacy of Tramadol can be decreased when used in combination with Panobinostat.
ParaldehydeTramadol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Tramadol.
PargylineTramadol may increase the neuroexcitatory activities of Pargyline.
ParoxetineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Paroxetine.
ParoxetineTramadol may increase the serotonergic activities of Paroxetine.
Peginterferon alfa-2bThe serum concentration of Tramadol can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tramadol.
PentazocinePentazocine may decrease the analgesic activities of Tramadol.
PentazocineThe risk or severity of adverse effects can be increased when Tramadol is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Tramadol.
PerampanelThe risk or severity of adverse effects can be increased when Tramadol is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Tramadol is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Tramadol.
PerphenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Pethidine.
PhenelzineTramadol may increase the neuroexcitatory activities of Phenelzine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Tramadol.
PhenindioneTramadol may increase the anticoagulant activities of Phenindione.
PheniprazineTramadol may increase the neuroexcitatory activities of Pheniprazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Tramadol is combined with Phenoxyethanol.
PhenoxypropazineTramadol may increase the neuroexcitatory activities of Phenoxypropazine.
PhenprocoumonTramadol may increase the anticoagulant activities of Phenprocoumon.
PhenterminePhentermine may increase the analgesic activities of Tramadol.
PhenytoinThe risk or severity of adverse effects can be increased when Tramadol is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Tramadol is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tramadol.
PipotiazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tramadol.
PiretanideThe risk or severity of adverse effects can be increased when Tramadol is combined with Piretanide.
PirlindoleTramadol may increase the neuroexcitatory activities of Pirlindole.
PivhydrazineTramadol may increase the neuroexcitatory activities of Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Tramadol is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Tramadol is combined with Pomalidomide.
PosaconazoleThe serum concentration of Tramadol can be increased when it is combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium Citrate.
PramipexoleTramadol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Tramadol is combined with Pregabalin.
PrilocaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Procarbazine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Tramadol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tramadol.
PromazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Tramadol.
PromethazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Tramadol.
ProparacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Proparacaine.
PropericiazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Tramadol is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Tramadol is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Tramadol is combined with PSD502.
QuazepamThe serum concentration of Tramadol can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Tramadol is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Quinethazone.
QuinidineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Quinidine.
QuinineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Tramadol is combined with Ramelteon.
RamosetronTramadol may increase the constipating activities of Ramosetron.
RanolazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ranolazine.
RasagilineTramadol may increase the neuroexcitatory activities of Rasagiline.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Tramadol.
RemifentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Tramadol is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Tramadol is combined with Reserpine.
RifabutinThe metabolism of Tramadol can be increased when combined with Rifabutin.
RifampicinThe metabolism of Tramadol can be increased when combined with Rifampicin.
RifapentineThe metabolism of Tramadol can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Risperidone.
RitonavirThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Rizatriptan.
RolapitantThe therapeutic efficacy of Tramadol can be decreased when used in combination with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Romifidine.
RopiniroleTramadol may increase the sedative activities of Ropinirole.
RopiniroleThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Ropivacaine.
RotigotineTramadol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tramadol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Tramadol is combined with S-Ethylisothiourea.
SafrazineTramadol may increase the neuroexcitatory activities of Safrazine.
SaquinavirThe serum concentration of Tramadol can be increased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tramadol.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tramadol.
SecobarbitalThe risk or severity of adverse effects can be increased when Tramadol is combined with Secobarbital.
SelegilineTramadol may increase the neuroexcitatory activities of Selegiline.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Tramadol.
SertindoleThe risk or severity of adverse effects can be increased when Tramadol is combined with Sertindole.
SertralineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Sertraline.
SertralineTramadol may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Tramadol is combined with Sevoflurane.
SildenafilThe metabolism of Tramadol can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Tramadol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Tramadol can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Tramadol is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Tramadol.
SorafenibThe metabolism of Tramadol can be decreased when combined with Sorafenib.
SpironolactoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Spironolactone.
St. John's WortThe serum concentration of Tramadol can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Stiripentol.
StiripentolThe risk or severity of adverse effects can be increased when Tramadol is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Tramadol.
SufentanilThe risk or severity of adverse effects can be increased when Tramadol is combined with Sufentanil.
SulfisoxazoleThe metabolism of Tramadol can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Tramadol is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Sumatriptan.
SuvorexantThe risk or severity of adverse effects can be increased when Tramadol is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Tramadol is combined with Tasimelteon.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Tramadol.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tramadol is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Tramadol can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Tramadol can be increased when it is combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Temazepam.
TerbinafineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tramadol is combined with Tetrodotoxin.
ThalidomideTramadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tramadol.
TheobromineThe risk or severity of adverse effects can be increased when Tramadol is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Tramadol.
ThiopentalThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiopental.
ThioproperazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tramadol.
ThioridazineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Thioridazine.
ThiotepaThe metabolism of Tramadol can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiagabine.
TianeptineTianeptine may increase the neuroexcitatory activities of Tramadol.
TiclopidineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Tramadol is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Tramadol.
TipranavirThe therapeutic efficacy of Tramadol can be decreased when used in combination with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tizanidine.
TocilizumabThe serum concentration of Tramadol can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tramadol is combined with Tolcapone.
ToloxatoneTramadol may increase the neuroexcitatory activities of Toloxatone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Tramadol.
TolvaptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Tramadol is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Tramadol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tramadol is combined with Tranylcypromine.
TrazodoneTramadol may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Tramadol.
TriamtereneThe risk or severity of adverse effects can be increased when Tramadol is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Tramadol is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Tramadol is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Tramadol.
TrifluoperazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Tramadol.
TriflupromazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tramadol.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Tramadol.
TrimipramineThe risk or severity of adverse effects can be increased when Tramadol is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Tramadol is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tramadol.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Tramadol.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Tramadol.
UlaritideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Tramadol.
Valproic AcidThe risk or severity of adverse effects can be increased when Tramadol is combined with Valproic Acid.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tramadol.
VenlafaxineThe therapeutic efficacy of Tramadol can be decreased when used in combination with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Tramadol is combined with Venlafaxine.
VerapamilThe metabolism of Tramadol can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Tramadol is combined with Vigabatrin.
VilazodoneVilazodone may increase the neuroexcitatory activities of Tramadol.
VilazodoneTramadol may increase the serotonergic activities of Vilazodone.
VoriconazoleThe serum concentration of Tramadol can be increased when it is combined with Voriconazole.
VortioxetineTramadol may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tramadol.
WarfarinTramadol may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Tramadol is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Tramadol is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Tramadol is combined with Ziconotide.
ZimelidineZimelidine may increase the neuroexcitatory activities of Tramadol.
ZimelidineTramadol may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe therapeutic efficacy of Tramadol can be decreased when used in combination with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Tramadol is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Tramadol is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Tramadol is combined with Zolmitriptan.
ZolpidemThe risk or severity of adverse effects can be increased when Tramadol is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Tramadol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Tramadol is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Tramadol is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zuclopenthixol.
Food Interactions
  • Oral administration of tramadol hydrochloride with food does not significantly affect its rate or extent of absorption, therefore, tramadol hydrochloride can be administered without regard to food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Gillen C, Haurand M, Kobelt DJ, Wnendt S: Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):116-21. [PubMed:10961373 ]
  2. Potschka H, Friderichs E, Loscher W: Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000 Sep;131(2):203-12. [PubMed:10991912 ]
  3. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL: Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992 Jan;260(1):275-85. [PubMed:1309873 ]
  4. Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. [PubMed:15509185 ]
  5. Ide S, Minami M, Ishihara K, Uhl GR, Sora I, Ikeda K: Mu opioid receptor-dependent and independent components in effects of tramadol. Neuropharmacology. 2006 Sep;51(3):651-8. Epub 2006 Jun 21. [PubMed:16793069 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Minami K, Uezono Y, Ueta Y: Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci. 2007 Mar;103(3):253-60. [PubMed:17380034 ]
  8. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36. [PubMed:8955860 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Sagata K, Minami K, Yanagihara N, Shiraishi M, Toyohira Y, Ueno S, Shigematsu A: Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg. 2002 Apr;94(4):901-6, table of contents. [PubMed:11916794 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Berrocoso E, Mico JA: Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression. Int J Neuropsychopharmacol. 2009 Sep;12(8):1033-44. doi: 10.1017/S1461145709000236. Epub 2009 Apr 3. [PubMed:19341511 ]
  4. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36. [PubMed:8955860 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Barann M, Urban B, Stamer U, Dorner Z, Bonisch H, Bruss M: Effects of tramadol and O-demethyl-tramadol on human 5-HT reuptake carriers and human 5-HT3A receptors: a possible mechanism for tramadol-induced early emesis. Eur J Pharmacol. 2006 Feb 15;531(1-3):54-8. Epub 2006 Jan 19. [PubMed:16427041 ]
  2. Driessen B, Reimann W: Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro. Br J Pharmacol. 1992 Jan;105(1):147-51. [PubMed:1596676 ]
  3. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B: Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996 Nov;46(11):1029-36. [PubMed:8955860 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Ogata J, Minami K, Uezono Y, Okamoto T, Shiraishi M, Shigematsu A, Ueta Y: The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents. [PubMed:15105221 ]
  2. Horishita T, Minami K, Uezono Y, Shiraishi M, Ogata J, Okamoto T, Shigematsu A: The tramadol metabolite, O-desmethyl tramadol, inhibits 5-hydroxytryptamine type 2C receptors expressed in Xenopus Oocytes. Pharmacology. 2006;77(2):93-9. Epub 2006 May 5. [PubMed:16679816 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Sun HL, Zheng JW, Wang K, Liu RK, Liang JH: Tramadol reduces the 5-HTP-induced head-twitch response in mice via the activation of mu and kappa opioid receptors. Life Sci. 2003 Jan 31;72(11):1221-30. [PubMed:12570923 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM: Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. doi: 10.1016/j.bmcl.2008.10.134. Epub 2008 Nov 7. [PubMed:19027293 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Hara K, Minami K, Sata T: The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Anesth Analg. 2005 May;100(5):1400-5, table of contents. [PubMed:15845694 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Not Available
Specific Function:
Not Available
Gene Name:
CHRNA7
Uniprot ID:
Q693P7
Molecular Weight:
2987.635 Da
References
  1. Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A, Shibuya I: Inhibitory effects of tramadol on nicotinic acetylcholine receptors in adrenal chromaffin cells and in Xenopus oocytes expressing alpha 7 receptors. Br J Pharmacol. 2002 May;136(2):207-16. [PubMed:12010769 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A: Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors. J Pharmacol Exp Ther. 2001 Oct;299(1):255-60. [PubMed:11561087 ]
  2. Shiga Y, Minami K, Shiraishi M, Uezono Y, Murasaki O, Kaibara M, Shigematsu A: The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M(3) receptors. Anesth Analg. 2002 Nov;95(5):1269-73, table of contents. [PubMed:12401609 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 03:38